Overview
- Fourth-quarter revenue was $11.46 billion versus the $11.8 billion consensus, while adjusted EPS of $1.50 matched expectations.
- Diagnostics fell 2.5% to $2.46 billion on lower COVID test demand and China’s volume-based procurement pressure, and nutrition declined 8.9% to $1.94 billion following price actions and promotions.
- Medical devices grew about 12% to $5.68 billion, led by electrophysiology, diabetes care and rhythm management, but the strength did not offset declines elsewhere.
- Abbott guided Q1 2026 adjusted EPS to $1.12–$1.18, below the roughly $1.20 Street view, and projected full-year EPS of $5.55–$5.80 with 6.5%–7.5% organic sales growth.
- Shares fell roughly 8%–10% to a new 52-week low as the company highlighted recent device approvals, including FDA clearance for the Volt PFA System and a CE Mark for TactiFlex Duo, and reaffirmed plans to close the ~ $21 billion Exact Sciences deal in Q2 2026.